{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T17:22:36Z","timestamp":1762104156040,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100020578","name":"Foundation S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020578","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010137","name":"Fondation Sanofi Espoir","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010137","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.bulcan.2025.07.011","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T11:45:03Z","timestamp":1758109503000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Les adaptations th\u00e9rapeutiques\u00a0: rationnel, acquis et limites. Exp\u00e9rience du GFAOP"],"prefix":"10.1016","author":[{"given":"Gabrielle Chantal","family":"Bouda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Patte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.bulcan.2025.07.011_bib0155","first-page":"2347","article-title":"D\u00e9but et d\u00e9veloppement de l\u2019oncologie p\u00e9diatrique","volume":"41","author":"Schweisguth","year":"1991","journal-title":"Rev Prat"},{"year":"1994","series-title":"L\u2019enfant le sang et l\u2019espoir","author":"Bernard","key":"10.1016\/j.bulcan.2025.07.011_bib0160"},{"key":"10.1016\/j.bulcan.2025.07.011_bib0165","series-title":"Cambridge World history of human disease","first-page":"224","article-title":"Infant mortality","author":"Stockwell","year":"1993"},{"key":"10.1016\/j.bulcan.2025.07.011_bib0170","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10269-016-2674-9","article-title":"Sp\u00e9cificit\u00e9s p\u00e9diatriques en canc\u00e9rologie","volume":"18","author":"Michon","year":"2016","journal-title":"Oncologie"},{"year":"2022","series-title":"Pour la vie des enfants souffrant de cancer","author":"Msefer Alaoui","key":"10.1016\/j.bulcan.2025.07.011_bib0175"},{"issue":"5","key":"10.1016\/j.bulcan.2025.07.011_bib0180","first-page":"497","article-title":"Le traitement des cancers de l\u2019enfant en afrique travaux du groupe franco-africain d\u2019oncologie p\u00e9diatrique","volume":"67","author":"Lemerle","year":"2007","journal-title":"Med Trop"},{"issue":"9","key":"10.1016\/j.bulcan.2025.07.011_bib0185","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1182\/blood-2007-09-112920","article-title":"Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169\u00a0unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95","volume":"111","author":"M\u00f6ricke","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2025.07.011_bib0190","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(21)00470-8","volume":"23","author":"Mauz-K\u00f6rholz","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2025.07.011_bib0195","doi-asserted-by":"crossref","first-page":"e26335","DOI":"10.1002\/pbc.26335","article-title":"Risk-adapted stratification for optimally intensive treatment assignment of pediatric patients with non-Hodgkin lymphoma is an effective strategy in developing countries","volume":"64","author":"Belgaumi","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"6432","key":"10.1016\/j.bulcan.2025.07.011_bib0200","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1126\/science.aaw4892","article-title":"Science and health for all children with cancer","volume":"363","author":"Lam","year":"2019","journal-title":"Science"},{"issue":"27","key":"10.1016\/j.bulcan.2025.07.011_bib0205","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2014.59.5827","article-title":"Non-hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead","volume":"33","author":"Minard-Colin","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2025.07.011_bib0210","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1200\/JCO.22.00230","article-title":"A population-based study of the long-term risk of infections associated with hospitalization in childhood cancer survivors","volume":"41","author":"Chehab","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2025.07.011_bib0215","doi-asserted-by":"crossref","first-page":"e2200044","DOI":"10.1200\/GO.22.00044","article-title":"Long-term outcomes in survivors of childhood cancer: a 30-year experience from India","volume":"8","author":"Prasad","year":"2022","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.bulcan.2025.07.011_bib0220","doi-asserted-by":"crossref","first-page":"102209","DOI":"10.1016\/j.canep.2022.102209","article-title":"Late effects of childhood cancer treatment in long-term survivors diagnosed before the age of 3\u00a0years\u00a0\u2013\u00a0A multicenter, nationwide study","volume":"80","author":"Latoch","year":"2022","journal-title":"Cancer Epidemiol"},{"issue":"S5","key":"10.1016\/j.bulcan.2025.07.011_bib0225","doi-asserted-by":"crossref","first-page":"e26879","DOI":"10.1002\/pbc.26879","article-title":"A framework to develop adapted treatment regimens to manage pediatric cancer in low- and middle-income countries: The Pediatric Oncology in Developing Countries (PODC) Committee of the International Pediatric Oncology Society (SIOP)","volume":"64","author":"Howard","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"5\u00a0Suppl. 1","key":"10.1016\/j.bulcan.2025.07.011_bib0230","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0929-693X(15)30034-8","article-title":"Curing Burkitt lymphomas, from France to Africa","volume":"22","author":"Patte","year":"2015","journal-title":"Arch Pediatr Org"},{"issue":"6","key":"10.1016\/j.bulcan.2025.07.011_bib0235","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/pbc.21452","article-title":"Treatment of B-cell lymphoma with LMB modified protocols in Africa\u2014report of the French-African Pediatric Oncology Group (GFAOP)","volume":"50","author":"Harif","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2025.07.011_bib0240","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/pbc.23284","article-title":"Treatment of nephroblastoma in Africa: results of the first French African pediatric oncology group (GFAOP) study","volume":"58","author":"Moreira","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2025.07.011_bib0245","first-page":"1","article-title":"Treatment of Wilms Tumor in Sub-Saharan Africa: Results of the Second French African Pediatric Oncology Group Study","author":"Yao","year":"2019","journal-title":"J Glob Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2025.07.011_bib0250","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08880018.2011.644881","article-title":"The Cameroon 2008\u00a0Burkitt lymphoma protocol: improved event-free survival with treatment adapted to disease stage and the response to induction therapy","volume":"29","author":"Hesseling","year":"2012","journal-title":"Pediatr Hematol Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2025.07.011_bib0255","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/pbc.20254","article-title":"The 2000\u00a0Burkitt lymphoma trial in Malawi","volume":"44","author":"Hesseling","year":"2005","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2025.07.011_bib0260","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pbc.22746","article-title":"Cyclophosphamide monotherapy in children with Burkitt lymphoma: a study from the French\u2013African Pediatric Oncology Group (GFAOP)","volume":"56","author":"Traor\u00e9","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2025.07.011_bib0265","first-page":"1","article-title":"Advanced Burkitt Lymphoma in Sub-Saharan Africa Pediatric Units: Results of the Third Prospective Multicenter Study of the Groupe Franco-Africain d\u2019Oncologie P\u00e9diatrique","author":"Bouda","year":"2019","journal-title":"J Glob Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2025.07.011_bib0270","doi-asserted-by":"crossref","first-page":"e27101","DOI":"10.1002\/pbc.27101","article-title":"Treatment of retinoblastoma in Sub-Saharan Africa: Experience of the paediatric oncology unit at Gabriel Toure Teaching Hospital and the Institute of African Tropical Ophthalmology, Bamako, Mali","volume":"65","author":"Traor\u00e9","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2025.07.011_bib0275","doi-asserted-by":"crossref","first-page":"155","DOI":"10.7196\/SAJCH.2020.v14i3.01723","article-title":"Treatment of childhood Hodgkin lymphoma in sub-Saharan Africa: A report from the French-African Paediatric Oncology Group (GFAOP)","volume":"14","author":"Diagne Akonde","year":"2020","journal-title":"South Afr J Child Health"},{"issue":"3","key":"10.1016\/j.bulcan.2025.07.011_bib0280","doi-asserted-by":"crossref","first-page":"e29464","DOI":"10.1002\/pbc.29464","article-title":"The development of an international childhood cancer hospital register database in 13\u00a0African countries.A project of the French African Pediatric Oncology Group (GFAOP)","volume":"69","author":"Mallon","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2025.07.011_bib0285","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.arcped.2020.12.002","article-title":"Integrating a palliative approach into the healthcare provided by the French-African Pediatric Oncology Group's pilot units. Insights from a 3-year training program","volume":"28","author":"Edan","year":"2021","journal-title":"Arch Pediatr"},{"issue":"23","key":"10.1016\/j.bulcan.2025.07.011_bib0290","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for high-risk, mature B-cell non-hodgkin's lymphoma in children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"N Engl J Med"},{"issue":"Suppl. 15","key":"10.1016\/j.bulcan.2025.07.011_bib0295","doi-asserted-by":"crossref","first-page":"10507","DOI":"10.1200\/JCO.2016.34.15_suppl.10507","volume":"34","author":"Minard-Colin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2025.07.011_bib0150","doi-asserted-by":"crossref","first-page":"e28682","DOI":"10.1002\/pbc.28682","article-title":"Increased toxicities in children with Burkitt lymphoma treated with rituximab: experience from a tertiary cancer center in India","volume":"67","author":"Srinivasan","year":"2020","journal-title":"Pediatr Blood Cancer"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125003819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125003819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T17:19:48Z","timestamp":1762103988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455125003819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":30,"alternative-id":["S0007455125003819"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.07.011","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les adaptations th\u00e9rapeutiques\u00a0: rationnel, acquis et limites. Exp\u00e9rience du GFAOP","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}